In the News: Drug Discovery and Development 2023 Predictions
Drug Discovery and Development highlighted key drug discovery and development predictions for 2023. Antheia was highlighted for its take...
top of page
Search
Antheia
- Oct 30, 2022
In the News: Contract Pharma, Leveraging Fermentation to Produce Complex APIs
In this Contract Pharma Q&A, we sat down with Kristin Brooks to discuss how our company uses fermentation to produce complex APIs for...
Antheia
- Apr 14, 2022
In the News: Antheia Senior Scientist Involved in Cancer Research Discovery
Senior Scientist Chunshun Li received accolades for his contribution to a recent University of Hawaii Cancer Center discovery. In support...
Antheia
- Jan 4, 2022
In the News: Seven Biopharma Trends to Watch in 2022
Dr. Christina Smolke provides visionary insight on the trends shaping biopharma in 2022. Against a backdrop of skeptical news about the...
Antheia
- Aug 18, 2021
Antheia to access Ginkgo’s enzyme screening and design technology
Ginkgo Bioworks, a Boston-based cell-programming specialist, will deploy its high-throughput enzyme design and screening technology to...
Antheia
- Aug 16, 2021
Brewing up plant-inspired medicines
Antheia reconstructs complex biochemical pathways in yeasts to speed up production of natural product-based drugs Read the article at:...
Antheia
- Aug 11, 2021
Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology...
With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell...
Antheia
- Jul 28, 2021
Biomanufacturing draws hundreds of millions in investments
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology Read the article at:...
Antheia
- Jul 8, 2021
Antheia raises $73 million for drugs from reprogrammed yeast
Antheia, a synthetic biology company cofounded and led by Stanford University bioengineer Christina Smolke, has raised $73 million in...
Antheia
- Jul 8, 2021
Antheia Secures $73M in Series B Funding
Antheia, a synthetic biology company working to develop plant-inspired medicine, has officially secured a fresh $73 million in Series B...
Antheia
- Jul 5, 2021
Startup using yeast to make drug components raises $73M
The idea: A California company producing active pharmaceutical ingredients with engineered yeast raised $73 million to bring its first...
Antheia
- Jul 2, 2021
Top 10 Synthetic Biology Companies
Any doubts about synthetic biology’s attractiveness to investors were likely shattered during the first quarter, when investors pumped...
Antheia
- Jun 30, 2021
Antheia Raises $73M in Series B Funding
Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors...
Antheia
- Jun 30, 2021
Synthetic-Biology Startup Antheia Raises $73 Million
Antheia Inc., a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new...
Antheia
- Jun 30, 2021
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its...
Antheia
- Jun 30, 2021
Say goodbye to plants: Synbio player Antheia earns new backers in quest to redesign flora-derived...
The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors...
Antheia
- Jun 30, 2021
Female-Founded Antheia Raises $73 Million to Support Synthetic Biology for Essential Medicines
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first...
Antheia
- Jun 29, 2021
Synthetic biology firm Antheia collects $73m Series B
Menlo Park, California-based Antheia, a synthetic biology company, has raised $73 million in Series B financing. Viking Global Investors...
Antheia
- Jun 29, 2021
Antheia Inks $73M Series B Financing Round
MENLO PARK, CA, Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series...
Antheia
- Jun 28, 2021
Antheia nabs $73M for synthetic biology platform
June 30, 2021 -- Antheia has raised $73 million to support the commercialization of its first pharmaceutical compound and the scale-up of...
Antheia Newsroom
bottom of page